Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T09:44:31.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Good news regarding SSRI safety in Danish meta-analysis

Published online by Cambridge University Press:  26 December 2019

Fredrik Hieronymus Open the ORCID record for Fredrik Hieronymus [Opens in a new window] ,
Alexander Lisinski ,
Jakob Näslund  and
Elias Eriksson
Fredrik Hieronymus
Affiliation:
Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Clinical Medicine, Aarhus University, Aarhus, Denmark Department of Affective Disorders, Aarhus University Hospital, Aarhus, Denmark
Alexander Lisinski
Affiliation:
Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Jakob Näslund
Affiliation:
Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Elias Eriksson*
Affiliation:
Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
*
Author for correspondence: Elias Eriksson, Email: elias.eriksson@neuro.gu.se
Get access Rights & Permissions [Opens in a new window]

Abstract

In two previous letters on an selective serotonin reuptake inhibitor (SSRI) meta-analysis conducted by the Copenhagen Trial Unit at Copenhagen University Hospital, we have commented on a large number of errors, almost all of which have tilted the results in an anti-drug direction, that unfortunately mar this publication. While the authors have acknowledged many of these mishaps, and may now be expected to submit an extensive errata list to the journal where their paper was once published, we regretfully note that also their latest contribution to this exchange is surprisingly inaccurate. However, its many shortcomings notwithstanding, their meta-analysis does add to the current literature by confirming that SSRIs do not seem to enhance the risk for suicide or death, and also that these drugs seem to enhance the risk of side effects categorised as serious only in the elderly.

Keywords

SSRIantidepressantsaffective disorderdepressionpsychiatric disorders
Type
Commentary
Information
Acta Neuropsychiatrica , Volume 32 , Issue 1 , February 2020 , pp. 54 - 56
Copyright
© Scandinavian College of Neuropsychopharmacology 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Copenhagen Trial Unit. Useful Information – Financial Structure. Available at http://www.ctu.dk/about-the-ctu/useful-information.aspx (accessed 15 October 2019).Google Scholar
Dragioti, E, Solmi, M, Favaro, A, Fusar-Poli, P, Dazzan, P, Thompson, T, Stubbs, B, Firth, J, Fornaro, M, Tsartsalis, D, Carvalho, AF, Vieta, E, McGuire, P, Young, AH, Shin, JI, Correll, CU and Evangelou, E (2019) Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76, 1241–1255. DOI: 10.1001/jamapsychiatry.2019.2859.CrossRefGoogle Scholar
Hieronymus, F, Lisinski, A, Naslund, J and Eriksson, E (2018a) Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have. Acta Neuropsychiatrica 30, 266–274.CrossRefGoogle ScholarPubMed
Hieronymus, F, Lisinski, A, Naslund, J and Eriksson, E (2018b) Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. Acta Neuropsychiatrica 30, 244–250.CrossRefGoogle ScholarPubMed
Hieronymus, F, Nilsson, S and Eriksson, E (2016) A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Translational Psychiatry 6, e834.CrossRefGoogle Scholar
Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Moller, K, Iversen, M, Banke, MB, Petersen, IJ, Klingenberg, SL, Krogh, J, Ebert, SE, Timm, A, Lindschou, J and Gluud, C (2017a) Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 58.CrossRefGoogle ScholarPubMed
Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Moller, K, Iversen, M, Banke, MB, Petersen, IJ, Klingenberg, SL, Krogh, J, Ebert, SE, Timm, A, Lindschou, J and Gluud, C (2017b) Erratum to: selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 162.CrossRefGoogle ScholarPubMed
Jindal, RD, Friedman, ES, Berman, SR, Fasiczka, AL, Howland, RH and Thase, ME (2003) Effects of sertraline on sleep architecture in patients with depression. Journal of Clinical Psychopharmacology 23, 540–548.CrossRefGoogle ScholarPubMed
Katakam, KK, Sethi, NJ, Jakobsen, JC and Gluud, C (2018) Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review. Acta Neuropsychiatrica 30, 251–265.CrossRefGoogle ScholarPubMed
Katakam, KK, Sethi, NJ, Jakobsen, JC and Gluud, C (2019) Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus et al. Acta Neuropsychiatrica 31, 276–284.CrossRefGoogle ScholarPubMed
Munkholm, K, Paludan-Muller, AS and Boesen, K (2019) Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open 9, e024886.CrossRefGoogle ScholarPubMed
Otte, A, Maier-Lenz, H and Dierckx, RA (2005) Good clinical practice: historical background and key aspects. Nuclear Medicine Communications 26, 563–574.CrossRefGoogle ScholarPubMed
Wegener, G and Rujescu, D (2013) The current development of CNS drug research. The International Journal of Neuropsychopharmacology 16, 1687–1693.CrossRefGoogle ScholarPubMed